These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 31847613

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach.
    Rex JH, Outterson K.
    Lancet Infect Dis; 2016 Apr; 16(4):500-5. PubMed ID: 27036356
    [Abstract] [Full Text] [Related]

  • 4. Repairing the broken market for antibiotic innovation.
    Outterson K, Powers JH, Daniel GW, McClellan MB.
    Health Aff (Millwood); 2015 Feb; 34(2):277-85. PubMed ID: 25646108
    [Abstract] [Full Text] [Related]

  • 5.
    Anderson M, Panteli D, Mossialos E.
    ; 2023 Feb. PubMed ID: 37582187
    [Abstract] [Full Text] [Related]

  • 6. What are the economic barriers of antibiotic R&D and how can we overcome them?
    Renwick M, Mossialos E.
    Expert Opin Drug Discov; 2018 Oct; 13(10):889-892. PubMed ID: 30175625
    [No Abstract] [Full Text] [Related]

  • 7. Combatting Antibiotic Resistance Together: How Can We Enlist the Help of Industry?
    Edwards SE, Morel CM, Busse R, Harbarth S.
    Antibiotics (Basel); 2018 Dec 18; 7(4):. PubMed ID: 30567308
    [Abstract] [Full Text] [Related]

  • 8. Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial Resistance.
    Årdal C, Røttingen JA, Opalska A, Van Hengel AJ, Larsen J.
    Clin Infect Dis; 2017 Oct 15; 65(8):1378-1382. PubMed ID: 29017240
    [Abstract] [Full Text] [Related]

  • 9. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps.
    Simpkin VL, Renwick MJ, Kelly R, Mossialos E.
    J Antibiot (Tokyo); 2017 Dec 15; 70(12):1087-1096. PubMed ID: 29089600
    [Abstract] [Full Text] [Related]

  • 10. The role of the pharmaceutical industry in meeting the public health threat of antibacterial resistance.
    Bergström R.
    Drug Resist Updat; 2011 Apr 15; 14(2):77-8. PubMed ID: 21493123
    [Abstract] [Full Text] [Related]

  • 11. Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus.
    Morel CM, Lindahl O, Harbarth S, de Kraker MEA, Edwards S, Hollis A.
    J Antibiot (Tokyo); 2020 Jul 15; 73(7):421-428. PubMed ID: 32203126
    [Abstract] [Full Text] [Related]

  • 12. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals.
    Kesselheim AS, Outterson K.
    Health Aff (Millwood); 2010 Sep 15; 29(9):1689-96. PubMed ID: 20820028
    [Abstract] [Full Text] [Related]

  • 13. Impact of antibiotic restrictions: the pharmaceutical perspective.
    Power E.
    Clin Microbiol Infect; 2006 Aug 15; 12 Suppl 5():25-34. PubMed ID: 16827822
    [Abstract] [Full Text] [Related]

  • 14. Antibiotic development: a victim of market forces?
    Tillotson GS.
    IDrugs; 2008 May 15; 11(5):340-6. PubMed ID: 18465675
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Market concentration of new antibiotic sales.
    Rahman S, Lindahl O, Morel CM, Hollis A.
    J Antibiot (Tokyo); 2021 Jun 15; 74(6):421-423. PubMed ID: 33664435
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The antibiotic pipeline: reviving research and development and speeding drugs to market.
    Luepke KH, Mohr JF.
    Expert Rev Anti Infect Ther; 2017 May 15; 15(5):425-433. PubMed ID: 28306360
    [Abstract] [Full Text] [Related]

  • 19. Antibiotic research and development: business as usual?
    Harbarth S, Theuretzbacher U, Hackett J, DRIVE-AB consortium.
    J Antimicrob Chemother; 2015 May 15; 70(6):1604-7. PubMed ID: 25673635
    [Abstract] [Full Text] [Related]

  • 20. Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance.
    Sciarretta K, Røttingen JA, Opalska A, Van Hengel AJ, Larsen J.
    Clin Infect Dis; 2016 Dec 01; 63(11):1470-1474. PubMed ID: 27578820
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.